HEALTH PLAN POLICY

Policy Title: Genetic Expression Profiling – Lung Cancer
Policy Number: MUM53
Revision: New
Department: Medical Management
Sub-Department: Utilization Management
Applies to Product Lines:
- Medicaid
- Children’s Health Insurance Plan
- Health Insurance Exchange
- Medicare
- USFHP
- Commercial Insured
- Non Insured Business

Origination/Effective Date: 10/09/2019
Reviewed Date(s): Revision Date(s):

SCOPE:

This policy addresses Genetic Expression Profiling (GEP) in patients with pulmonary lesions identified by CAT scan.

DEFINITIONS AND ACRONYMS:

- Communicable Disease Center (CDC)
- Computed Axial Tomography (CAT)
- Genetic Expression Profiling (GEP)
- Non Small Cell Lung Cancer (NSCLC)

POLICY:

This is an investigational study without medical necessity.

RATIONALE:

Lung cancer is the most common cause of cancer mortality and the third most common malignancy. NCCN does not mention GEP as a tool for further evaluating pulmonary nodules. False negative results from GEP can delay diagnosis and contribute to poor outcomes. No prospective, randomized studies have been done to establish clinical utility.

REFERENCES:

- NCCN 2019 Algorithms for Lung Cancer
- CDC 2018 Incidence and Mortality of Lung Cancer

RELATED DOCUMENTS:

None
HEALTH PLAN POLICY

Policy Title: Genetic Expression Profiling – Lung Cancer
Policy Number: MUM53
Revision: New

Nancy Horstmann
Chief Executive Officer Health Plans

David Engleking, M.D.
Medical Director

10/14/19
10/15/19

REVISION HISTORY:

<table>
<thead>
<tr>
<th>Revision</th>
<th>Date</th>
<th>Description of Change</th>
<th>Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>New</td>
<td>10/09/19</td>
<td>Initial release</td>
<td>Executive Leadership</td>
</tr>
</tbody>
</table>

Page 2 of 2